Endo Misrepresented Opioid Drug Safety, Shareholder Says
Endo International PLC misrepresented the safety of its opioid Opana ER, ultimately causing the company to pull the drug from the market and the stock price to plunge, according to a...To view the full article, register now.
Already a subscriber? Click here to view full article